India Glycols Demerger: Restructuring Unlocks Value with Aggressive Bio-Chemicals Growth Targets
India Glycols Ltd 路 Investor Presentation 路 02 Sept 2026, 10:20 pm
India Glycols Demerger: Restructuring Unlocks Value with Aggressive Bio-Chemicals Growth Targets India Glycols executed a three-way demerger effective 1st Sep'26, spinning off its Spirits and Biopharma units into independent listed companies. Investors receive one IGL Spirits share per IGL share, and one Ennature share for every three IGL shares. The retained entity focuses on bio-based specialty chemicals, reporting FY26 net sales of INR 1,164 Cr and an adjusted EBITDA of INR 330 Cr (28.4% margin). Driven by a renewable-carbon strategy, management targets INR 2,000 Cr in net revenue and INR 400 Cr EBITDA within 4-5 years.
Original exchange filing (PDF)
More announcements from India Glycols Ltd
- Please find attached. 路 17 Nov 2026
- Please find atached. 路 13 Nov 2026
- India Glycols Limited has informed the Exchange about General Updates 路 13 Nov 2026
- Please find attached. 路 13 Nov 2026
- India Glycols Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026. 路 13 Nov 2026
- Please refer to attachment. 路 13 Nov 2026
- Please find attached 路 18 Nov 2026
- Please find attached 路 18 Nov 2026
